Biomea Fusion Inc (BMEA)

Nov 18, 2024

Late-Breaker Oral Presentation Showing New Analysis from - GlobeNewswire

Nov 18, 2024

Nov 18, 2024

Biomea Fusion's Diabetes Drug Shows 1.23% HbA1c Drop in Key Patient Group | BMEA Stock News - StockTitan

Nov 18, 2024

Nov 17, 2024

(BMEA) Investment Report - Stock Traders Daily

Nov 17, 2024

Nov 13, 2024

We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Yahoo Finance

Nov 13, 2024

Nov 06, 2024

How To Trade (BMEA) - Stock Traders Daily

Nov 06, 2024

Nov 05, 2024

Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World

Nov 05, 2024

Nov 04, 2024

Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India

Nov 04, 2024

Nov 04, 2024

Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World

Nov 04, 2024

Nov 04, 2024

HC Wainwright Forecasts Increased Earnings for Biomea Fusion - MarketBeat

Nov 04, 2024

Nov 04, 2024

Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

Nov 04, 2024

Nov 04, 2024

Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 04, 2024

Nov 02, 2024

BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan

Nov 02, 2024

Nov 01, 2024

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024

Nov 01, 2024

Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia

Nov 01, 2024

Oct 31, 2024

HC Wainwright Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat

Oct 31, 2024

Oct 31, 2024

Biomea Fusion Unveils Promising Diabetes Treatment Innovations - TipRanks

Oct 31, 2024

Oct 30, 2024

Biomea Fusion Reports Q3 2024 Financial Results - MSN

Oct 30, 2024

Oct 30, 2024

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - GlobeNewswire

Oct 30, 2024

Oct 30, 2024

Barclays Forecasts Strong Price Appreciation for Biomea Fusion (NASDAQ:BMEA) Stock - MarketBeat

Oct 30, 2024

Oct 30, 2024

Biomea Awaits 2 Data Readouts Of Diabetes StudiesCan The Stock Get Its Mojo Back? - RTTNews

Oct 30, 2024

Oct 30, 2024

Biomea Fusion (NASDAQ:BMEA) Announces Earnings Results - MarketBeat

Oct 30, 2024

Oct 30, 2024

Biomea Fusion price target raised to $11 from $9 at Barclays - TipRanks

Oct 30, 2024

Oct 29, 2024

Biomea Fusion reports Q3 EPS (91c), consensus (95c) - TipRanks

Oct 29, 2024

Oct 29, 2024

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times

Oct 29, 2024

Oct 28, 2024

Biomea Fusion options imply 6.1% move in share price post-earnings - TipRanks

Oct 28, 2024

Oct 28, 2024

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages - MarketBeat

Oct 28, 2024

Oct 28, 2024

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Oct 28, 2024

Oct 27, 2024

(BMEA) Technical Data - Stock Traders Daily

Oct 27, 2024

Oct 22, 2024

Biomea Fusion shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia

Oct 22, 2024

Oct 22, 2024

Biomea Fusion's (BMEA) Buy Rating Reiterated at HC Wainwright - MarketBeat

Oct 22, 2024

Oct 22, 2024

Biomea Fusion shares maintain Buy rating from H.C. Wainwright - Investing.com

Oct 22, 2024

Oct 22, 2024

Exchange Traded Concepts LLC Acquires 8,079 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World

Oct 22, 2024

Oct 21, 2024

Biomea Fusion's icovamenib gets global and US naming approval - Investing.com India

Oct 21, 2024

Oct 21, 2024

Biomea Fusion's icovamenib gets global and US naming approval By Investing.com - Investing.com South Africa

Oct 21, 2024

Oct 21, 2024

Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219 - TipRanks

Oct 21, 2024

Oct 21, 2024

Biomea Fusion Announces Approval of 'icovamenib” as International Nonproprietary Name for BMF-219 - The Manila Times

Oct 21, 2024

Oct 21, 2024

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 - GlobeNewswire

Oct 21, 2024

Oct 19, 2024

Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World

Oct 19, 2024

Oct 16, 2024

(BMEA) Investment Analysis and Advice - Stock Traders Daily

Oct 16, 2024

Oct 16, 2024

Griffin Asset Management Inc. Purchases 57,180 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat

Oct 16, 2024

Oct 15, 2024

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-21 - The Manila Times

Oct 15, 2024

Oct 13, 2024

Marshall Wace LLP Sells 3,900 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World

Oct 13, 2024

Oct 13, 2024

Squarepoint Ops LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat

Oct 13, 2024

Oct 12, 2024

Investigation Launched into Biomea Fusion Securities - Bit Perfect Solutions

Oct 12, 2024

Oct 10, 2024

Biomea Fusion (NASDAQ:BMEA) Upgraded at EF Hutton Acquisition Co. I - MarketBeat

Oct 10, 2024